Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Protealis NV has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to examiner KARUNASENA, ENUSHA, the 1 distinct examiner for the company. The prosecution is focused in 1 distinct art unit. KARUNASENA, ENUSHA is the busiest examiner with 1 pending office action. This indicates a focused prosecution profile with the only pending action under the review of a single official in the biotechnology sector.
The presence of 1 distinct examiner for the 1 pending office action means that the applicant can focus their legal strategy on a single set of examiner preferences. Since the work is contained within 1 distinct art unit, the technical scope is likely narrow and specialized. Practitioners should tailor their arguments to the specific standards of the Biotechnology & Pharmaceuticals area as interpreted by the assigned official. This concentrated activity in 1 distinct art unit simplifies the management of the portfolio, as there are no competing examiner perspectives to reconcile. The alignment of the pending action with a single examiner and art unit provides a clear path for prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KARUNASENA, ENUSHA | 1 | 25.0% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18839719 | Plant Growth Promoting Bradyrhizobium Compositions | KARUNASENA, ENUSHA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18839719 | Plant Growth Promoting Bradyrhizobium Compositions | KARUNASENA, ENUSHA | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839719 | Plant Growth Promoting Bradyrhizobium Compositions | KARUNASENA, ENUSHA | 1614 | §102§103§112 | Non-Final OA | — | Pending | Aug 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProtealis NV has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Enusha Karunasena has the most, with 1 of Protealis NV's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
